Prediction: The Weight-Loss Drug Boom Could Be Just the Beginning for Lilly
Eli Lilly (LLY) raised its full-year revenue guidance to $91B-$92B, up from $85B-$87B, driven by strong performance in weight-loss drugs like Mounjaro and Zepbound. 24/7 Wall St. set a 12-month price target of $1,618.86, implying 14.2% upside. Q3 revenue grew 38.6% YoY to $24.4B, exceeding estimates. Bulls cite potential from new drugs and Medicare expansion, while bears highlight pricing pressures.
How this was made
The 30-second read
Why it matters
The guidance lift and earnings beat provide a fresh catalyst that could drive the stock higher in the short term.
Market read
Eli Lilly's strong Q3 performance and raised guidance make the stock a near‑term buy candidate.
What to watch
Potential regulatory delays for retatrutide and price erosion from Medicare/Medicaid expansion.
Background
The article is a price‑target and guidance update from 24/7 Wall St., focusing on Eli Lilly's weight‑loss franchise.
Ticker impact
Eli Lilly raised full-year revenue guidance to $91‑$92 billion and reported Q3 results beating estimates, providing fresh material that can move the stock.
likely upward as investors price in higher growth and revenue outlook
The new guidance and strong Q3 numbers are first‑report facts; analysts upgraded the stock and set a higher price target, creating a clear buying signal.
Market effects
Strengthens the pharma/biotech sector outlook on GLP‑1 obesity drugs.
U.S. market may see modest rally in health‑care stocks.
Highlights competitive pressure on Novo Nordisk and Merck globally.
Counterpoint
Price may be capped by falling tirzepatide net prices and upcoming pricing pressure.
Key entities
- companyEli Lilly
US‑listed pharmaceutical company (ticker LLY).
